JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic Significance of Volumetric Parameters on Pretreatment FDG PET/CT in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Therapy

  • 0Department of Nuclear Medicine, Soonchunhyang University Cheonan Hospital, Cheonan.
Clinical Nuclear Medicine +

|

April 21, 2025

|

April 21, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Total Lesion Glycolysis (TLG) on FDG PET/CT predicts outcomes for hepatocellular carcinoma (HCC) patients receiving atezolizumab and bevacizumab. Higher TLG indicates poorer progression-free survival (PFS) and overall survival (OS).

Area Of Science

  • Oncology
  • Radiology
  • Nuclear Medicine

Background

  • Hepatocellular carcinoma (HCC) treatment response can be difficult to predict.
  • Atezolizumab plus bevacizumab is a standard therapy for advanced HCC.
  • FDG PET/CT parameters may offer prognostic value.

Purpose Of The Study

  • To evaluate the prognostic significance of FDG PET/CT parameters.
  • To predict progression-free survival (PFS) and overall survival (OS) in HCC patients.
  • To assess the utility of these parameters in patients treated with atezolizumab plus bevacizumab.

Main Methods

  • Retrospective analysis of 78 HCC patients.
  • FDG PET/CT imaging before treatment.
  • Measurement of SUVmax, tumor-to-normal liver uptake ratio, metabolic tumor volume, and total lesion glycolysis (TLG) for intrahepatic lesions.
  • Measurement of extrahepatic SUVmax for metastatic lesions.

Main Results

  • Higher TLG values were observed in patients with progressive disease compared to responders (P < 0.05).
  • TLG independently predicted both PFS (P = 0.019) and OS (P = 0.003) in multivariate analysis.
  • Metabolic tumor volume and extrahepatic SUVmax also showed significant associations with survival outcomes.

Conclusions

  • TLG in intrahepatic HCC lesions is significantly associated with treatment response.
  • TLG serves as an independent prognostic factor for PFS and OS.
  • TLG is a potential imaging biomarker for predicting clinical outcomes in HCC patients receiving atezolizumab plus bevacizumab.

Keywords: